121,980 Shares in Twist Bioscience Corporation $TWST Acquired by Legal & General Group Plc

Key Points

• Legal & General Group Plc acquired 121,980 shares of Twist Bioscience during the second quarter, valued at approximately $12.5 million and representing about 0.19% of the company.
• Analysts remain broadly positive, with a consensus rating of “Moderate Buy” and an average price target of $98.30, although the stock has recently traded as high as $155.44.
• Twist Bioscience reported quarterly revenue of $118.38 million, up 23.2% year over year, but missed the EPS estimate and posted a loss of $0.56 per share. Insiders sold about 193,099 shares worth $24.0 million over the past 90 days.

Legal & General Group Plc acquired a new stake in shares of Twist Bioscience Corporation (NASDAQ:TWST - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 121,980 shares of the company's stock, valued at approximately $12,549,000. Legal & General Group Plc owned approximately 0.19% of Twist Bioscience as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. ARK Investment Management LLC raised its holdings in shares of Twist Bioscience by 12.4% during the 4th quarter. ARK Investment Management LLC now owns 7,559,495 shares of the company's stock valued at $239,787,000 after purchasing an additional 832,687 shares in the last quarter. William Blair Investment Management LLC increased its position in Twist Bioscience by 43.7% during the fourth quarter. William Blair Investment Management LLC now owns 5,954,429 shares of the company's stock worth $188,874,000 after buying an additional 1,812,146 shares during the last quarter. BlackRock Inc. bought a new position in Twist Bioscience during the second quarter valued at about $600,191,000. EdgePoint Investment Group Inc. raised its holdings in Twist Bioscience by 31.7% during the fourth quarter. EdgePoint Investment Group Inc. now owns 5,377,991 shares of the company's stock valued at $170,590,000 after buying an additional 1,295,672 shares in the last quarter. Finally, State Street Corp lifted its position in shares of Twist Bioscience by 17.4% in the fourth quarter. State Street Corp now owns 3,627,818 shares of the company's stock worth $115,074,000 after buying an additional 538,755 shares during the last quarter.

Wall Street Analysts Forecast Growth

TWST has been the subject of several recent analyst reports. Canaccord Genuity Group upped their price target on Twist Bioscience from $90.00 to $120.00 and gave the stock a "buy" rating in a research note on Tuesday, July 14th. Leerink Partners set a $110.00 target price on Twist Bioscience in a report on Thursday, July 16th. Robert W. Baird upped their target price on Twist Bioscience from $113.00 to $115.00 and gave the stock an "outperform" rating in a research report on Tuesday, August 4th. TD Cowen reaffirmed a "buy" rating on shares of Twist Bioscience in a research report on Monday, August 3rd. Finally, Guggenheim reissued a "buy" rating on shares of Twist Bioscience in a research report on Monday, August 24th. Eight equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Twist Bioscience currently has a consensus rating of "Moderate Buy" and an average price target of $98.30.

Insider Transactions at Twist Bioscience

In other news, CFO Adam Laponis sold 2,399 shares of the stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $94.33, for a total value of $226,297.67. Following the completion of the transaction, the chief financial officer owned 110,276 shares in the company, valued at approximately $10,402,335.08. This represents a 2.13% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Emily M. Leproust sold 113,318 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $125.16, for a total transaction of $14,182,880.88. Following the completion of the transaction, the chief executive officer owned 818,938 shares of the company's stock, valued at approximately $102,498,280.08. This represents a 12.16% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 193,099 shares of company stock valued at $24,026,581 in the last ninety days. 3.08% of the stock is owned by company insiders.

Twist Bioscience Trading Down 1.7%

Twist Bioscience stock opened at $139.00 on Tuesday. The business has a 50 day moving average price of $108.03 and a two-hundred day moving average price of $74.64. The company has a quick ratio of 2.38, a current ratio of 2.67 and a debt-to-equity ratio of 0.03. The stock has a market cap of $8.72 billion, a price-to-earnings ratio of -62.61 and a beta of 2.14. Twist Bioscience Corporation has a 12 month low of $23.30 and a 12 month high of $155.44.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings data on Monday, August 3rd. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.05). The firm had revenue of $118.38 million for the quarter, compared to analyst estimates of $114.55 million. Twist Bioscience had a negative return on equity of 28.64% and a negative net margin of 31.66%.Twist Bioscience's revenue for the quarter was up 23.2% compared to the same quarter last year. During the same period in the previous year, the business posted $0.33 EPS. As a group, equities analysts forecast that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Twist Bioscience Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist's offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source